ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2021
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06520397 (Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States.Journal of pediatric gastroenterology and nutrition · 2026Article
- 6-mercaptopurine and tofacitinib alter microbial protein expression but not composition in fecal microbiota incubations from Crohn's disease patients.BMC biology · 2026Article
- Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Practical Considerations for the Treatment of Patients with Psoriatic Arthritis and Comorbid Inflammatory Bowel Disease.Rheumatic diseases clinics of North America · 2025Review
- JAK Inhibitor and Crohn's Disease.Biomedicines · 2025Review
- Tofacitinib in Stricturing Colonic Crohn's Disease.ACG case reports journal · 2025Article
- Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium.Inflammatory bowel diseases · 2025Article
- Peri-Operative Optimization of Patients with Crohn's Disease.Current gastroenterology reports · 2024Review
- Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?Gastroenterology & hepatology · 2023Article
- Review
- Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease.Digestive diseases and sciences · 2022Article
- Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease.Inflammatory bowel diseases · 2022Article
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib.ACG case reports journal · 2021Article
- The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.International journal of molecular sciences · 2021Review
- Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- The Role of IL-35 in the Pathophysiological Processes of Liver Disease.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 1 country.
Funding
Abstract
The safety and efficacy of tofacitinib in Crohn's disease (CD) has been studied in 2 phase II trials in patients with moderate-to-severe CD with no new safety signals observed, but no significant difference from placebo in the primary efficacy endpoint of clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.